Show simple item record

dc.contributor.authorMateo, Jen_US
dc.contributor.authorSharp, Aen_US
dc.contributor.authorde Bono, JSen_US
dc.coverage.spatialSwitzerlanden_US
dc.date.accessioned2018-02-16T09:31:47Z
dc.date.issued2017-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28233594en_US
dc.identifierS0302-2838(17)30094-5en_US
dc.identifier.citationEur Urol, 2017, 72 (2), pp. 201 - 204en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1162
dc.identifier.eissn1873-7560en_US
dc.identifier.doi10.1016/j.eururo.2017.02.005en_US
dc.format.extent201 - 204en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectGenomicsen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectReceptors, Androgenen_US
dc.titleInvestigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?en_US
dc.typeJournal Article
dcterms.dateAccepted2017-02-03en_US
rioxxterms.versionofrecord10.1016/j.eururo.2017.02.005en_US
rioxxterms.licenseref.startdate2017-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEur Urolen_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume72en_US
pubs.embargo.termsNot knownen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthorMarsden,en_US
dc.contributor.icrauthorMateo Valderrama, Joaquinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record